Morning thoughts about IMCL future
1. Analysts assumptions that AMGN will price Pani substantially cheaper Erbitux are outright stupid and/or deliberately false.
AMGN understands very well that BMY/IMCL are both POS [it is not a big secret: we all know this, so AMGN]. Consequently, why should AMGN lose future Pani revenues pricing it low? No any reason for doing it. AMGN will price Pani very close to the present Erb price and out-market Erby by portraying Pani as "similar" to Erby in efficacy and superior in safety!
2. IMCL's BOD has no intention to sale IMCL. They are quite happy with the present situation collecting a lot of money by doing nothing. Following the sale, the gravy-train will stop. Therefore, the Lazar affair was just a smokescreen.
What does it mean?
Institutions might be very hesitant to allow Carl taking over IMCL but they will be more than willing to get rid of IMCL for a "good" price. And here, institutions and Carl will get together kicking out BOD ass.
When will it take place?
As soon as Erb reports good clinical data in 1st- and/or 2nd-lines mCRC and/or in pancreatic settings, IMCL will be sold!
